Blood Bank Market Size, Share, Growth, and Industry Analysis, By Type (Blood (Whole Blood), Platelets, Plasma, Double Red Cells), By Application (Hospitals, Laboratories, Blood Centers, Others), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

BLOOD BANK MARKET OVERVIEW

The global blood bank market size is USD 18.26 Billion in 2026 and is projected to reach USD 31.89 Billion by 2035, growing at a CAGR of 6.39% from 2026 to 2035.

The blood bank market forms a critical part of global healthcare infrastructure by supporting blood collection, component separation, testing, storage, compatibility assessment, and transfusion. More than 118 million blood donations are collected each year globally, demonstrating the scale of blood banking operations required for hospitals, trauma centers, oncology departments, and surgical facilities. Whole blood, platelets, plasma, and double red cells represent the major product categories. Automation is increasingly transforming donor screening, blood typing, component processing, and inventory management. Advanced blood screening technologies can achieve testing accuracy above 99%, while pathogen reduction systems are strengthening protection against transfusion-transmitted infections and improving blood component safety.

The United States blood bank market is supported by a highly developed network of hospitals, independent blood centers, plasma collection facilities, diagnostic laboratories, and transfusion medicine specialists. Demand remains closely connected with trauma care, cardiovascular procedures, cancer treatment, organ transplantation, emergency medicine, and chronic disease management. Automated component separation, molecular blood screening, RFID-based inventory management, and digital donor scheduling are increasingly incorporated into blood banking workflows. Large national organizations and regional blood centers operate extensive donor recruitment programs to maintain adequate inventories. Plasma collection is particularly important within the United States because of substantial domestic requirements for plasma-derived medicines and specialized therapeutic products.

KEY FINDINGS

LATEST TRENDS

The blood bank market is shifting toward automated collection, digital inventory management, pathogen reduction, molecular screening, and data-driven donor engagement. Automated donor screening systems represented 49% of new installations in large blood centers, demonstrating the growing importance of workflow automation. Blood centers increasingly use integrated software to schedule donors, monitor blood component availability, predict shortages, maintain traceability, and coordinate distribution with hospitals.

Advanced microbial testing can support platelet storage for up to 7 days under approved conditions. Another significant blood bank market trend is the adoption of automated whole blood processing. Systems integrating blood component separation with software platforms can standardize processing and reduce manual intervention. RFID tracking, barcode identification, connected refrigerators, temperature sensors, and automated alarms are improving cold-chain management.

MARKET DYNAMICS

DRIVER

Rising transfusion requirements from surgery, trauma, oncology, and chronic disease treatment.

Blood transfusion requirements remain the primary driver of the blood bank market. More than 118 million blood donations are collected globally each year, yet availability differs substantially between developed and developing healthcare systems. Surgical procedures, trauma treatment, severe anemia, childbirth complications, cancer therapy, cardiovascular intervention, and organ transplantation generate continuous requirements for blood components. Hospitals increasingly maintain separate inventories of red cells, platelets, and plasma to match specific clinical requirements. Aging populations also increase exposure to procedures requiring transfusion support. Oncology departments generate particularly important platelet demand because chemotherapy can substantially reduce platelet counts. Expanding intensive care infrastructure and emergency medicine capabilities further increase requirements for reliable blood collection, testing, storage, and distribution networks.

Drivers Impact Analysis*

RESTRAINT

Persistent donor shortages and limited storage life of blood components.

Blood bank operators face significant restraints because blood cannot be manufactured conventionally and inventories remain dependent on eligible donors. Maintaining regular donor participation is difficult during holidays, extreme weather events, infectious disease outbreaks, and demographic changes. Platelets create an additional inventory challenge because approved storage periods are considerably shorter than those of frozen plasma. Modern bacterial screening approaches can permit platelet storage for up to 7 days under applicable requirements, but expiration continues to create operational pressure. Blood centers must carefully balance collection schedules with hospital demand to prevent both shortages and wastage. Rural areas face additional transportation and cold-chain limitations. Recruiting rare blood-type donors also remains difficult, particularly for patients requiring repeated transfusions and closely matched components.

Restraints Impact Analysis*

Expansion of automated processing, pathogen reduction, and digital blood management.

Opportunity

Automation represents a major opportunity across the blood bank market because collection centers need higher throughput, standardized processing, stronger traceability, and lower dependence on manual workflows. Automated whole blood processing systems can separate collected blood into red cells, platelets, and plasma while integrated software platforms support workflow monitoring. Digital inventory platforms provide real-time visibility into available units, expiration status, blood type, storage location, and hospital requirements.

Maintaining blood safety, cold-chain integrity, regulatory compliance, and reliable supply.

Challenge

Blood bank operations require strict quality controls from donor selection through transfusion. Screening must address infectious agents while immunohematology laboratories must accurately determine blood groups, antibodies, and compatibility. Molecular screening technologies can deliver testing precision above 99% in advanced laboratory environments, but equipment availability and trained personnel remain uneven globally. Maintaining controlled storage temperatures during collection, processing, transportation, and hospital distribution is another critical challenge.

•   
•   
  

  Download Free Sample to learn more about this report

    

BLOOD BANK MARKET SEGMENTATION

By Type

Based on Type, the global market can be categorized into Blood (Whole Blood), Platelets, Plasma, and Double Red Cells.

• Blood (Whole Blood): Whole blood accounts for 43% of the blood bank market by type, making it the leading segment. Whole blood collection provides a flexible starting material because collected units can subsequently be separated into clinically useful components. Trauma treatment, emergency medicine, surgery, severe hemorrhage management, and military medicine support utilization. Global blood collection exceeds 118 million donations annually, providing a substantial operational base for whole blood processing.

• Platelets: Platelets account for 18% of the blood bank market by type and remain essential for oncology, hematology, transplantation, major surgery, and severe bleeding management. Cancer treatment represents a particularly important source of platelet demand because chemotherapy and hematological malignancies can cause thrombocytopenia. Platelets require intensive inventory planning because they have a substantially shorter storage period than frozen plasma.

• Plasma: Plasma represents 29% of blood bank market type activity. Demand comes from transfusion medicine and the production of plasma-derived therapies, including immunoglobulins and coagulation-related products. Plasma can be frozen, providing significantly greater inventory flexibility than platelets. Collection organizations increasingly deploy automated plasmapheresis equipment to improve donor workflow, collection consistency, and operational productivity.

• Double Red Cells: Double red cells account for 10% of the blood bank market by type. Automated apheresis enables collection of 2 red cell units from an eligible donor while returning other blood components during the procedure. This approach can improve collection efficiency for selected donor profiles and support inventories of frequently required red cell types. Double red cell collection is particularly useful for hospitals managing cardiovascular surgery, trauma, severe anemia, and complex transfusion requirements.

By Application

Based on Application, the global market can be categorized into Hospitals, Laboratories, Blood Centers, and Others.

• Hospitals: Hospitals represent 51% of blood bank market applications, making them the largest application segment. Demand is generated by operating rooms, emergency departments, intensive care units, oncology centers, maternity units, transplant programs, and cardiovascular departments. Hospitals require continuous access to red cells, platelets, plasma, and specialized components while maintaining strict compatibility and traceability procedures.

• Laboratories: Laboratories account for 14% of blood bank market applications. Their role includes blood typing, antibody screening, compatibility testing, infectious disease screening, microbial testing, and quality control. Modern immunohematology laboratories increasingly deploy automated analyzers that reduce manual intervention and improve sample processing consistency. Advanced molecular screening technologies can achieve testing precision above 99% in appropriate diagnostic settings.

• Blood Centers: Blood centers represent 27% of blood bank market applications. These organizations perform donor recruitment, blood collection, component preparation, testing, storage, inventory management, and distribution. More than 60% of blood collection activity in many centralized systems can be coordinated through dedicated collection organizations and associated donation facilities. Automation is increasingly important for processing whole blood and conducting apheresis collections.

• Others: Others account for 8% of blood bank market applications and include military healthcare systems, research institutions, specialized clinics, academic organizations, and emergency preparedness agencies. Military medicine requires dependable blood supplies for trauma response and remote operations, while research institutions use blood components for transfusion science, immunology, cell biology, and therapeutic development. Academic laboratories also contribute to research involving storage methods, pathogen reduction, compatibility, and next-generation blood products. Specialized clinics require components for hematological and chronic disease treatment.

•   
•   
  Download Free Sample to learn more about this report

    

BLOOD BANK MARKET REGIONAL INSIGHTS

• North America

North America accounts for 44% of the global blood bank market, making it the leading regional market. The United States provides the majority of regional activity through extensive hospital systems, independent blood centers, plasma collection facilities, and transfusion laboratories. 13.6 million whole blood and red cell donations are collected annually in the United States. Daily clinical requirements include substantial quantities of red cells, platelets, and plasma across trauma, oncology, surgical, and chronic disease treatment settings.

• Europe

Europe holds 23% of the global blood bank market. The region benefits from established public healthcare systems, organized transfusion services, widespread voluntary donation programs, and sophisticated immunohematology laboratories. European countries collectively record more than 25 million blood donations annually. Germany, France, Italy, Spain, and the United Kingdom maintain extensive hospital transfusion networks and specialized blood processing infrastructure. European laboratories increasingly adopt automated blood typing, compatibility testing, pathogen screening, and digital traceability solutions.

• Asia Pacific

Asia Pacific accounts for 25% of the global blood bank market and represents an important expansion area. China, India, Japan, South Korea, and Australia maintain substantial blood collection and transfusion systems, while Southeast Asian markets continue expanding hospital and diagnostic infrastructure. India records more than 14 million blood collections annually across its healthcare system. China continues investing in storage, testing, hospital infrastructure, and centralized blood services. Japan operates a mature transfusion network supported by established national blood collection programs.

• Middle East & Africa

Middle East & Africa represents 3% of the global blood bank market. Regional development varies considerably because Gulf healthcare systems operate advanced hospital and laboratory infrastructure while several African markets continue addressing donor availability, testing capacity, refrigeration, and transportation challenges. Saudi Arabia, the United Arab Emirates, and South Africa represent important centers for transfusion medicine investment. Trauma care, surgical procedures, maternity services, sickle cell disease management, and emergency medicine contribute to regional blood requirements. Sickle cell disease creates particularly important requirements for matched red blood cell availability across parts of Africa and the Middle East.

• Rest of the World

Rest of the World accounts for 5% of the global blood bank market, led primarily by Latin American blood collection and transfusion systems. Brazil, Argentina, Colombia, Chile, and neighboring markets maintain expanding networks of public hospitals, private healthcare facilities, laboratories, and blood centers. Regional demand is supported by trauma treatment, surgical procedures, cancer care, maternal health, and chronic disease management. Blood banking modernization increasingly focuses on infectious disease testing, donor recruitment, cold storage, traceability, and component processing.

KEY INDUSTRY PLAYERS

The blood bank market includes global plasma specialists, diagnostic companies, blood processing technology manufacturers, national blood services, and transfusion organizations. Grifols, CSL, Haemonetics, Terumo BCT, Fresenius Kabi, Cerus, Abbott, Bio-Rad Laboratories, BD, and bioMérieux maintain important positions across collection, screening, processing, diagnostics, and transfusion safety. Competition increasingly centers on automation, donor efficiency, pathogen reduction, molecular testing, immunohematology, digital connectivity, and plasma collection. Strategic partnerships with hospitals and blood centers support technology deployment. National organizations including American Red Cross, Canadian Blood Services, Japan Red Cross Society, and Sanquin strengthen collection networks, donor recruitment, research, and blood supply resilience.

List of Top Blood Bank Companies

• LFB Group
• Abbott
• Shire (Baxalta)
• Sichuan Yuanda Shuyang
• Grifols
• Kawasumi
• Bio-Rad Laboratories
• CBPO
• bioMérieux
• MacoPharma
• BD
• Japan Red Cross Society
• America’s Blood Centers
• CSL
• Octapharma
• Kedrion
• RAAS
• Cerus
• Fresenius Kabi
• Beckman Coulter
• American Red Cross
• BPL
• Biotest
• New York Blood Center
• Sanquin Blood Supply Foundation
• Ortho-Clinical
• Immucor
• Hualan Bio
• Canadian Blood Services
• Haemonetics
• Terumo BCT

LEADER INSIGHTS

• Grifols: Nacho Abia, Chief Executive Officer, emphasized that Grifols remains focused on sustainable growth while investing in long-term opportunities across its plasma network. The company sees increasing immunoglobulin demand, plasma self-sufficiency initiatives, regional supply diversification, and expanded collection capacity in Egypt as important drivers of future growth and supply resilience. (Published: July 28, 2026 | Source: https://www.grifols.com)

• CSL: Gordon Naylor, Interim Chief Executive Officer and Managing Director, stated that plasma market fundamentals and therapy demand remain robust, supporting CSL’s return to sustainable growth. His comments highlight continued investment in plasma collection productivity, manufacturing capacity, commercial capabilities, and next-generation technologies to meet growing demand for immunoglobulin and other plasma-derived therapies. (Published: August 18, 2026 | Source: https://investors.csl.com)

• Terumo BCT: Chetan Makam, General Manager of Global Blood Solutions, highlighted that blood centers are facing rising demand alongside staffing constraints and donor variability, increasing the importance of automation. His comments indicate that automated whole-blood processing is becoming strategic infrastructure for improving platelet availability, processing consistency, operational efficiency, and the resilience of hospital blood supplies. (Published: February 12, 2026 | Source: https://www.terumobct.com)

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment in the blood bank market increasingly targets automation, plasma collection, cold-chain modernization, molecular screening, pathogen reduction, and digital donor management. Automated blood collection equipment installations are expanding as healthcare institutions seek standardized workflows and higher processing efficiency. Digital platforms provide opportunities through donor scheduling, inventory forecasting, compatibility management, and component traceability. Plasma infrastructure remains another major investment area because immunoglobulin and specialized therapy production depends on reliable collection networks. Emerging healthcare systems provide opportunities for mobile donation centers and decentralized storage infrastructure. Modern cold-chain projects can reduce component wastage by 16%, strengthening the investment case for connected refrigerators and temperature-monitoring systems.

NEW PRODUCT DEVELOPMENT

Blood bank product development increasingly focuses on automated component processing, personalized plasma collection, pathogen reduction, rapid immunohematology, and molecular donor screening. Next-generation automated platforms are reducing manual sample handling and improving laboratory workflow consistency. Haemonetics received clearance for NexSys PCS with Persona PLUS technology following clinical evaluation involving more than 30,000 plasma donations. Grifols introduced Evanzys IH as a modular automated immunohematology platform designed to simplify sample processing and strengthen blood typing workflows. Manufacturers are also advancing LED-based pathogen reduction equipment, connected collection platforms, smart refrigerators, RFID blood tracking, automated separation systems, and software capable of integrating donor, laboratory, processing, and inventory information.

RECENT DEVELOPMENTS

• June 2026 – Next-generation Evanzys IH platform advances automated transfusion laboratory operations. Grifols launched Evanzys IH, combining modular automation and immunohematology processing to reduce manual intervention, improve laboratory flexibility, and accelerate safer blood typing workflows.

• February 2026 – FDA clears personalized NexSys PCS plasma collection technology for donors. Haemonetics secured FDA clearance for NexSys PCS with Persona PLUS, using personalized collection technology supported by clinical evaluation exceeding 30,000 plasma donation procedures.

REPORT COVERAGE

The blood bank market report covers collection, processing, testing, storage, transportation, transfusion, plasma collection, and blood safety technologies. Type analysis includes whole blood at 43%, plasma at 29%, platelets at 18%, and double red cells at 10%. Application coverage evaluates hospitals, laboratories, blood centers, and other specialized users. Regional analysis examines North America, Europe, Asia Pacific, Middle East & Africa, and Rest of the World. Competitive coverage evaluates major blood service organizations, plasma companies, diagnostics manufacturers, and automation suppliers. The report additionally assesses pathogen reduction, molecular screening, immunohematology automation, apheresis, donor management, digital inventory systems, cold-chain infrastructure, investments, and product innovation.